Format

Send to

Choose Destination
Neurosci Biobehav Rev. 2017 Sep;80:36-56. doi: 10.1016/j.neubiorev.2017.05.007. Epub 2017 May 12.

Oxytocin effects in schizophrenia: Reconciling mixed findings and moving forward.

Author information

1
Department of Psychiatry, University of California, San Francisco, 401 Parnassus Avenue, San Francisco, CA 94143, United States. Electronic address: ellen.bradley@ucsf.edu.
2
Department of Psychiatry, University of California, San Francisco, 401 Parnassus Avenue, San Francisco, CA 94143, United States.

Abstract

Schizophrenia is a severe mental illness that causes major functional impairment. Current pharmacologic treatments are inadequate, particularly for addressing negative and cognitive symptoms of the disorder. Oxytocin, a neuropeptide known to moderate social behaviors, has been investigated as a potential therapeutic for schizophrenia in recent years. Results have been decidedly mixed, leading to controversy regarding oxytocin's utility. In this review, we outline several considerations for interpreting the extant literature and propose a focused agenda for future work that builds on the most compelling findings regarding oxytocin effects in schizophrenia to date. Specifically, we examine underlying causes of heterogeneity in randomized clinical trials (RCTs) conducted thus far and highlight the complexity of the human oxytocin system. We then review evidence of oxytocin's effects on specific deficits in schizophrenia, arguing for further study using objective, precise outcome measures in order to determine whether oxytocin has the potential to improve functional impairment in schizophrenia.

KEYWORDS:

Negative symptoms; Oxytocin; Schizophrenia; Social cognition

PMID:
28506922
PMCID:
PMC5682229
DOI:
10.1016/j.neubiorev.2017.05.007
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center